Posttransplant lymphoproliferative disorders.
Posttransplant lymphoproliferative disorder is a heterogeneous group of clonal hyperplasia/neoplasms that can range from benign to highly malignant lesions. Mortality rates can approach 60%. This entity has been on the rise for the last 2 decades with the advent of highly potent immunosuppressive agents. Epstein-Barr virus has shown to play a primary role in more than 90% of the cases. Although standard protocols do not exist for primary prevention and treatment, new agents are emerging that may play a role in treatment and prevention of this debilitating, and at times, fatal disease.
Chughtai
Asim
A
Division of Nephrology, Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri 63110, USA.
Bastani
Bahar
B
D020031:Epstein-Barr Virus Infections / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D012307:Risk Factors; D019737:Transplants / Q000009:adverse effects* / Q000821:virology
D007166:Immunosuppressive Agents